In general, a disease manifests not from malfunction of individual molecules but from failure of the relevant system or network, which can be considered as a set of interactions or edges among molecules. Thus, instead of individual molecules, networks or edges are stable forms to reliably characterize complex diseases. This paper reviews both traditional node biomarkers and edge biomarkers, which have been newly proposed. These biomarkers are classified in terms of their contained information. In particular, we show that edge and network biomarkers provide novel ways of stably and reliably diagnosing the disease state of a sample. First, we categorize the biomarkers based on the information used in the learning and prediction steps. We then briefly introduce conventional node biomarkers, or molecular biomarkers without network information, and their computational approaches. The main focus of this paper is edge and network biomarkers, which exploit network information to improve the accuracy of diagnosis and prognosis. Moreover, by extracting both network and dynamic information from the data, we can develop dynamical network and edge biomarkers. These biomarkers not only diagnose the immediate pre-disease state but also detect the critical molecules or networks by which the biological system progresses from the healthy to the disease state. The identified critical molecules can be used as drug targets, and the critical state indicates the critical point of disease control. The paper also discusses representative biomarker-based methods.
Most complex diseases are caused by multiple factors, which must be investigated in a systematic and dynamical manner [13] . From a systems biology viewpoint, a disease results not from the malfunction of individual molecules but from failure of the relevant system or network, which can be considered as a set of interactions or edges among molecules. Thus, complex diseases can be more reliably characterized by networks or edges than by single molecules (i.e., genes, proteins, metabolites and other measurable biological elements). Network features can be used to indicate the state of a disease (diagnosis), estimate the effect of treatment or predict the survival time (prognosis). Networks and edges of biomolecules also play important roles in the phenotypic variations among plants and animals, which can be similarly used for the classification and prediction of phenotypes in evolutionary studies.
Traditionally, researchers have used genetic or biomolecular biomarkers, also known as gene signatures or molecular biomarkers respectively, to distinguish particular biological phenotypes (e.g., states of complex diseases). In conventional clinical study, molecular biomarkers are widely used for (i) diagnosing a disease state and (ii) predicting the outcome of a disease state (prognosis). The growing popularity of "P4 medicine", i.e., predictive, preventive, personalized and participatory medicine has diverted our attention from passive treatment of disease to active prevention [2] . To reach the lofty targets of modern biomedical studies, early-warning signals should be detected and disease states should be predicted before the occurrence or serious deterioration of disease. Such early intervention can halt the disease before it progresses to an irreversible state. Obviously, conventional molecular biomarkers are not directly applicable to "P4 medicine" because they reflect biological elements rather than the predictors/causes of a disease. On the other hand, biological functions and signal transductions are facilitated by interactions (regulations) between molecules, which constitute the edges in biological networks. Thus, P4 medicine relies on the networks and interactions among biological elements (such as genes, proteins and patients) rather than the biological elements themselves. Network analysis captures previously unobserved features in both the network (edges) and dynamics. Therefore, as our theoretical and clinical thinking has advanced, biomarkers have evolved from single molecules (e.g., individual genes) to multiple molecules (e.g., gene sets), associated molecules (e.g., molecular networks) and finally to dynamical interactive molecules (e.g., dynamical molecule networks). From a network perspective, biomarkers are classified as node biomarkers, networkbased biomarkers, network-weighted biomarkers, network (edge) biomarkers, and dynamical network biomarkers (DNBs) or dynamical edge biomarkers, as shown in Table 1 . In particular, as components of general network biomarkers [4] , edge biomarkers exploit information of interactions or associations among molecules, rather than individual molecules. Many researchers have investigated the influence of perturbations on interaction networks. Perturbations fall into two categories; loss of gene products ('node removal', the removal of a node from the interaction network), and loss of protein or gene interactions ('edge removal', the removal of an edge from the interaction network). Recently, 'edgetic' disease has been identified as the result of an interaction removal (edge removal) rather than a gene removal (node removal) [5] . On the other hand, our recent EdgeMarker analysis [6] demonstrated that non-differentially expressed genes, which are traditionally ignored, can be as informative as differentially expressed genes for classifying biological conditions and sample phenotypes. All of the above studies indicate that edge biomarkers can provide new insights into the pathogenesis of complex diseases at the network level. The strength of an edge between two molecules is frequently determined by the molecules' co-expression, measured by the Pearson's correlation coefficient (PCC) [6] .
Next, we give a comprehensive review of the traditional node biomarker and the contemporary edge biomarker, and demonstrate the importance of edge biomarkers in translational biomedicine study. In Section 1, we first classify biomarkers based on the network information used in the learning and predicting steps. Section 2 briefly introduces conventional node biomarkers without network information, while Section 3 describes the biological background and motivation of node biomarkers with network information in the learning procedure. Section 4 presents the major topic of this paper: the use of edge biomarkers with network information in both learning and predicting procedures. Particular emphasis is placed on dynamical edge biomarkers, which exploit both network and dynamical information, and thus can detect pre-disease states that are missed by traditional biomarkers. Sections 2, 3 and 4 are accompanied by the computational approaches used to analyze the respective biomarkers. The paper concludes with several general remarks on biomarkers.
Categories of biomarkers
Biomarkers can be identified from observed samples or data (in a machine learning context) by a two-step process of learning and predicting. In the learning step, effective marker molecules that distinguish different phenotypes in samples are identified. Phenotypic examples are control and case samples, or normal and disease samples. The prediction step decides the candidate phenotype of a test sample based on the identified marker molecules. Depending on the data used for learning and predicting, biomarkers [4] are grouped into several broad categories as shown in Table 1 . Besides traditional node (molecular) biomarkers, these categories include network-based biomarkers and network-weighted biomarkers, which use molecular network to identify sub-networks or edges from sample data in the learning step, but use only those molecules (or molecule set) related to the edges or sub-networks in the prediction step. Although sub-networks and edges are identified by network or correlation information, the edge or network information is excluded from the phenotypic prediction; thus, network-based and network-weighted biomarkers are essentially node biomarkers. In contrast, edge biomarkers, which include network biomarkers and dynamical network biomarkers (DNBs), use network or edge information in both learning and predicting steps. As such, they form networks of marker molecules and are essentially different from node biomarkers. Rather than merely diagnosing a disease state, DNBs exploit dynamical information in the data [711], and thus can detect pre-disease states (or early-warning disease signals), which cannot be determined by traditional biomarkers. Note that the pre-disease state can be viewed as a special normal state immediately before the major deterioration or critical transition of a disease [4] . In Table 1 , biomarkers are also categorized by whether one or multiple samples are used in the predicting step. In contrast to node biomarkers, which are typically represented by differential expressions (i.e., the first-order statistics) of individual molecules or a molecular set, edge biomarkers exploit the association or correlation information among molecules to predict the phenotype of a test sample. These associations are represented by differential correlations and differential deviations (i.e., the second-order statistics) of molecules. The additional information provided by correlations or interactions not only improves the accuracy of phenotype prediction, but also reveals the biological or pathogenic mechanism underlying the marker molecules (e.g., the driver genes). Furthermore, by including the dynamic information of data, dynamical network biomarkers (or dynamical edge biomarkers) can diagnose a "pre-disease" or "un-occurred disease" state at an early stage. This concept is not new; it has been mentioned in Yellow Emperor's Medicine (one of the earliest books on traditional Chinese medicine) 2000 years ago.
Node biomarkers for classification and prediction without network information
Node (or molecular) biomarkers have been widely studied, especially for detecting and combating complex diseases. For instance, (i) the tumor suppressor genes BRCA1 and BRCA2, mainly involved in DNA damage repair and transcriptional regulation, are well-known causal genes of breast, ovarian and similar cancers [12] . The chromosomal stability of these genes is altered by mutations. Somatic alterations weaken the genes' suppressor ability, loosening their control on proliferation and ultimately leading to tumor occurrence and development. (ii) Pre-diabetic individuals show significant metabolic variations of a few important metabolites [13] , which are expected to become novel markers for distinguishing impaired glucose tolerant (IGT) individuals from those with normal glucose tolerance. If pre-diabetic individuals with impaired glucose tolerance are treated early, their metabolisms can recover to the nor-mal state, avoiding the development of Type 2 diabetes (T2D). Thus, this small number of IGT-specific metabolites and their associated T2D-related genes/proteins could be newly exploited in T2D prevention. (iii) In the case of pain, neurological and psychiatric diseases, the acid-sensing ion channels (ASICs) play important roles in the central and peripheral nervous systems [14] . Investigations of these ASICs have revealed the molecular mechanism of extracellular acid sensing by neurons. Potential inhibiting or potentiating ASICs cause physiological and behavioral disorders, leading to disease occurrence and development. Collectively, these studies have shown that one or a few molecules (e.g., master regulators) are important molecular indicators of the establishment and progression of complex diseases.
In addition to conventional low-throughput technologies, high-throughput approaches (such as microarrays) have provided big data for identifying molecular biomarkers, enabling cheap effective methods for predicting human disease risk. At the level of conventional node biomarkers, these methods demonstrate the effectiveness of classifying samples by individual molecules at different scales, i.e., single genes and sets of genes. Several single genes have been already identified as disease biomarkers, especially in cancers. An example is the IL28B gene implicated in liver cancer [15, 16] . More importantly, the driver mutations of genes have been identified in a genome-wide association study [17] using next-generation sequencing technology [18] . Genes inducing pathogenic physical changes are usually drivers rather than passengers of disease consequents [19] . However, gene sets [20] are known to improve the classification accuracy of marking complex disease phenotypes, for the following reason. Unlike hereditary diseases, which always occur by mutations on a few genes, cancer and metabolic diseases (and many other complex diseases) [2123] are usually caused by numerous associated genes. There are different strategies for predicting disease states from sets of marker genes. First, the normal and disease states can be distinguished by differential expression of the identified marker genes [24] . Second, a common discriminative gene group can be mined from multiple datasets [25] , or multiple classifiers can be integrated from sets of marker genes [26, 27] . These approaches enhance the robustness or consensus of sets of expression-dependent marker genes in heterogeneous disease cohorts. Finally, disease phenotypes can be characterized by differential enrichment rather than by differential expression [2831]; the so-called enrichment-based approach or activity-based method [31, 32] . According to this approach, pathogenic genotypes are characterized by significant extent and number of differentially regulated genes in a particular gene set.
Although conventional node biomarkers have greatly advanced the study of disease diagnosis, several formidable problems remain, including improved diagnostic accuracy, early diagnosis before the disease occurs or clinical symptoms appear, and therapy prediction. While these problems have been identified in conventional node biomarker studies, their solution requires biomarkers that integrate network information and even dynamical information, such as (dynamical) edge biomarkers. Such biomarkers have been extensively proposed and investigated in recent years [4, 33, 34] , and are described in the next sections.
Node biomarkers for classification and prediction with network information limited to the learning step
Biomarkers that integrate network information have received much attention in recent translational biomedical research. Many studies have shown that signaling pathways, protein complexes, and sub-networks have more discriminative power for identifying disease phenotypes than individual gene and protein expression. For instance, condition-responsive genes (CORGs) integrate pathway information or biological network into a new measurement of gene signatures [32] , providing more robust indicators for characterizing disease samples. Similarly, a newly proposed multi-pathway-based method called Pathifier [35] transforms gene-level information into pathway-level information by a pathway deregulation score. Pathifier has revealed highly reproducible, well-preserved and significant biological features of complex diseases. Many researchers have explored the causal associations between gene pairs and phenotypes to understand how perturbations influence interactome networks. As mentioned in the Introduction, perturbations are of two types; loss of gene products ('node removal', or removal of a node from the interactome network), and loss of gene interactions ('edge removal', or removal of an edge from the interactome network). Interaction (edge) removals, rather than gene (node) removals, are responsible for the so-called 'edgetic' diseases [5] . Thus, differentially expressed interactions or networks can provide more details about human pathogenic states and realize better molecular therapeutic strategies than conventional differentially expressed genes.
Because network-associated biomarkers integrate differential gene expression and differential expression correlations among genes, they characterize diseases in a reliable manner. Depending on the input and output data included in the learning and predicting steps (Table 1) , biomarkers with network information are roughly divided into networkbased biomarkers, network-weighted biomarkers, network (or edge) biomarkers, and DNBs or dynamical edge biomarkers. Unlike other types of biomarkers, edge biomarkers use network information to enhance the power of marker genes and their associations in both the learning and prediction steps.
Network-based biomarkers use the network information only for selecting a set of molecules (or marker molecules) from a static background network in the learning step.
These marker molecules and their expressions are then used to identify the phenotype (e.g., normal or disease) of a test sample in the prediction step. Similarly, network-weighted biomarkers select marker molecules based on the network information. These markers, together with their expressions, are then weighted by the network topology before being input to the prediction step for phenotypic identification. Clearly, although network information (e.g., correlation) is used in the learning step, it is disregarded in the prediction step. Therefore, both network-based and network-weighted biomarkers are essentially node biomarkers. However, network information is difficult to apply on a single test sample in the prediction step because, unlike gene expression, pairs of molecules or edges cannot be easily correlated in a single sample.
On the other hand, network and edge biomarkers use static network information (e.g., background protein interaction networks) or dynamical network information (e.g., co-expression networks) to identify integrative marker molecules and their marker molecule-pairs (or marker edges). These marker edges are then used in both learning and predicting steps. In particular, since DNBs or dynamical edge biomarkers extend the dynamical information to the prediction step, they can detect the pre-disease (or pretransition) state immediately prior to disease occurrence. Clearly, because they exploit edges or networks, these biomarkers can exist as simple network or edge biomarkers or can form a network of biomarkers. In addition, the difficulty of representing an edge or network using a single sample has been recently overcome [6] , which greatly improves the feasibility of edge biomarkers in clinical practice. Representative biomarkers with network information are summarized in Table 2 . Network-associated biomarkers are detailed in the following subsections.
Network-based biomarkers
Chuang et al. [36] proposed the PinnacleZ approach for identifying so-called network markers. Network markers are not individual genes but sub-networks extracted from a protein interaction network. In PinnacleZ, the activity of each sub-network is defined as the regularized mean expression of the genes within it, and cancers are classified by the module activity profile rather than by the gene expression profile. Dao et al. [37] adopted to identify discriminative sub-network markers by a color coding technique implemented in a network-based classification algorithm called OptDis. In this approach, features are sub-network markers rather than single genes, and feature values (marker expressions) are the average expression levels of genes in the sub-network. He et al. [38] proposed a network-based approach that identifies dysfunctional modules (DM) in context-specific protein-protein interaction networks, and classifies phenotypes by the aggregated expression activity of gene modules (e.g., the regularized mean expression of genes in a module). Jin et al. [40] developed an integrative pipeline for biomarker discovery (IPBD) that combines disease information and expression profiles for proteins and genes with protein-protein interactions. Indeed, Jin et al.'s paper coined the term "network biomarker". For each sample, the intensity (expression) of a network biomarker is the weighted sum of intensities of genes in the network, where the weights are the P-values of the differential expression of each gene. Winter et al. [41] implemented a network-based approach called NetRank, which is similar to Google's PageRank. This method ranks genes by their prognostic relevance based on both expression and network information. The expression levels of the identified predictive marker genes are directly learned by a support vector machine, and the prognoses of tumor samples are categorized as poor or good. Eddy et al. [39] designed Differential Rank Conservation (DIRAC), a rank-based algorithm that considers the combinatorial effect of gene interactions within a network (the pathways) and evaluate the differential network rankings by quantitative measures such as rank difference scores. It should be noted that these quantitative measures are based on the ordering of gene expressions within the network but disregard the topological structure of the network. Obviously, all of the above methods extract discriminative gene sets constrained by the prior network in the learning step, but exclude the network or edge information in the prediction step. Therefore, these biomarkers are essentially node biomarkers, at least from the viewpoint of biomarker application.
Network-weighted biomarkers
Alternatively, marker molecules can be identified from the prior network (with static network topology) in the learning step (see Class I network-weighted biomarkers in Table 2 ). The CORGs based classification method proposed by Lee et al. [32] infers the activity level of a given pathway by summarizing the gene expression levels of the CORGs. Although Lee et al. do not consider the topological structure of the pathway, this information could be accommodated in the method. The DART (denoising algorithm based on relevance network topology) algorithm, recently designed by Jiao et al. [42] , improves pathway activity estimates by filtering out noise in advance. The algorithm first builds a pruned expression relevance network (as a co-expression network of genes), in which the noiseless pathway activity is computed as a metric on the largest connected component (e.g., the maximal connected sub-network of relevance network). Similar to the previous sub-network expression metric [32] , the activity metric may be sign-weighted, which registers whether the genes involved in pathway regulation are up-or down-regulated, or topologically weighted, which considers the number of neighbors of a single gene on the relevance network. Recently, Wen et al. [43] developed a network-based approach that identifies the putative causal module (PCM) biomarkers of complex diseases by integrating epigenomic data, gene expression data, and protein-protein interaction networks. In this method, the modules are extracted from the protein interaction network by a Markov clustering algorithm (MCL), and their activities are defined as the degree-weighted mean expression of genes in each module. Dutkowski et al. used the network-guided forests (NGF) algorithm to identify logic functions (e.g., decision trees) with the same topological structure as the sub-networks in a prior network [45] . NGF is expected to connect the activity of each predictive module to the activity of its component genes. Hofree et al. [44] implemented a novel network-based stratification method (NBS) that integrates tumor somatic mutations with gene networks. In several steps, this method builds a robust stratification of patients (subtypes). First, it prepares the binary mutation profiles, then projects these profiles onto a human gene interaction network. A 'network-smoothed' profile is generated by network propagation and entered into the NetNMF algorithm, which clusters patients into subtypes. Patient assignments are then consolidated by consensus clustering. This method also classifies mutation-derived subtypes, based on which an mRNA expression signature can also be applied for subtype prediction.
Other methods identify molecular markers from extracted discriminative gene sets constrained by the correlation network in the learning step (see Class II network-weighted biomarkers in Table 2 ). Taylor et al. [47] investigated changes in the organization of the interactome and their predictive relations with patient outcomes. They identified tissue-specific inter-modular hub proteins and tissuecommon intra-modular hub proteins. Each hub protein and its co-expressed interacting partners constitute one module (DHP: dynamical hub and partner). Individual patients are assessed not by their gene expressions, but by their differing expressions of significant hubs and their interactors. Meanwhile, using protein association models, Wang et al. [48] constructed a network-based biomarker (CRV) that identifies proteins implicated in carcinogenesis and performs diagnostic evaluation. The CRV provides two protein association networks corresponding to the normal and disease states. In particular, a new sample can be classified as normal or diseased based on the mapping errors of its gene expressions onto the two protein association networks. Liu et al. [46] presented a differential network based approach (CDN: core of differential networks) for identifying disease genes and dysfunctional sub-networks during multi-stage cancer progression. In CDN, the module biomarkers of disease risk are sets of genes (where risk is evaluated from overlapping genes among differential networks corresponding to different cancer developmental stages). However, similarly to their network-based counterparts, networkweighted biomarker methods extract the discriminative gene sets constrained by the network in the learning step, but ignore the network or edge information in the prediction step. Thus, weighted biomarkers are also essentially node biomarkers. In fact, network-weighted biomarkers and follow-up network (or edge) biomarkers are very similar; the main difference is that network-weighted biomarkers (such as DHP [47] and CRV [48] ) recognize discriminative molecules (nodes) in the learning step, whereas network biomarkers identify discriminative molecule-pairs (edges).
We reiterate that all of the above network-based and network-weighted biomarkers are node biomarkers rather than edge or network biomarkers. Both categories examine the expressions of individual marker molecules in the prediction step. Network-weighted biomarkers must also estimate the expression weights in the learning step, since the weights must balance the trade-off between the learning and prediction accuracies. Network-weighted biomarkers-I (of Class I in Table 2 ) and network-weighted biomarkers-II (of Class II in Table 2 ) differ chiefly in that the former uses a static network structure while the latter uses a dynamical network structure. Thus, Class II network-weighted biomarkers can be expected to not only identify discriminative molecules as disease markers but also reveal condition-specific interactive maps among molecules, by which researchers could unravel disease mechanisms.
Edge biomarkers for classification and prediction with network information in both learning and predicting steps
The main advantage of edge biomarkers (or dynamical edge biomarkers) is their inclusion of network information in the prediction step. Note that predicting human phenotype generally requires several samples for calculating the correlations among nodes/genes (e.g., Pearson's correlation coefficient) or edge/gene pairs (higher-order statistics or correlations). In clinical practice, however, diagnosis or prognosis is evaluated on individuals. Constructing and interpreting correlation-like information in the prediction step of phenotypic diagnosis is difficult when very few test samples are available. To address this problem, several studies have investigated the edge biomarkers of single samples. Mathematical and computational approaches for phenotype prediction are broadly classifiable into multi-sample-based approaches (if multiple samples are available for use in the prediction step) [50] and single-sample-based approaches (if a single sample is available) [10] . Note that a group of nodes constitutes a node set, but a group of edges is a network. This implies that edge biomarkers are equivalent to biomarker networks. Representative analysis methods for network and edge biomarkers and their dynamical equivalents are discussed in the following subsections.
Network and edge biomarkers
Qian et al. [49] proposed a multi-sample-based approach for analyzing Class I network and edge biomarkers. Their method, called CTN (classifying time series gene expression via integration of biological networks) improves the classification and realizes reliable and sound predictions [49] . CTN hybridizes a hidden Markov model (HMM) and Gaussian mixture models (GMMs) to explore the time-dependence of the expression data, and thereby improve the prediction results. The learning step first infers the gene states by the HMM/GMM hybrid model, which converts the original gene expression level into a discrete gene state. Gene biclusters of each patient are then extracted from the temporal gene state matrix by a QL-biclustering algorithm, based on the suffix string and longest common prefix extracts. Each bicluster is assigned a PPI score based on the connection of its contained genes within the protein-protein interaction network (PPI). In the prediction step, the phenotype of each test patient is predicted by PPI-SVM-KNN (where KNN denotes k-nearest neighbors algorithm) according to the bicluster similarity (Jaccard index) of the patient and the PPI score of the bicluster. In experiments, learning of the early-stage data improved the performance of the later-stage phenotype prediction.
The EdgeMaker approach of Zhang et al. [6] is a single-sample-based approach for Class II network and edge biomarkers. EdgeMaker identifies edge biomarkers (differentially correlated gene pairs) by representing the edges in a new vector format. This method optimizes the classification ability and overcomes the difficulty of using edge information from a single sample in the prediction step, because each edge is represented as a correlation-like vector. EdgeMarker can predict or diagnose the phenotype of individual samples from the edge information, which is a major advantage of the method. In particular, theoretical and computational experiments show that the obtained edge biomarkers accurately distinguish phenotypes even when their genes are not differentially expressed. The results also support that non-differentially expressed genes, which are usually ignored by traditional methods, can be as informative as differentially expressed genes when assigning a biological condition or phenotype to a sample [6] . This finding provides new insight into the pathogenesis of complex diseases.
Dynamical network biomarkers and dynamical edge biomarkers
Chen et al. [7] developed a multi-sample-based approach for Class I dynamical network and edge biomarkers. This approach fully utilizes the second-order statistics, i.e., the expression deviations and inter-molecular correlations, to detect pre-disease rather than conventional disease states [7] . Here, the pre-disease state is defined as the normal state of an individual immediately before critical transition to the disease state, i.e., the limit of the normal state. Traditional node and edge biomarkers can distinguish between disease and normal states, but usually cannot diagnose the pre-disease state [7] because the molecular expressions of normal and early disease states are not significantly different. DNBs do distinguish between the pre-disease and normal states because they detect the early-warning signals of complex diseases regardless of sample size [7, 8] . Identification of DNB molecules (a group of molecules) is based on the following theory: as the system approaches the pre-disease state or the critical transition, (i) the expression of the DNB molecules dramatically deviates from that of the normal state; (ii) the expression correlation between any two DNB molecules increases; (iii) the expression correlation between any molecule in the DNB and any molecule in the non-DNB decreases. Unlike the critical slowing-down theory [51], DNB theory does not require a large number of samples from each individual, and detects the early-warning signals of critical transitions directly from the high-dimensional data. Thus DNB is a model-free approach for observing big data.
Inspired by the DNB, Yu et al. [50] proposed an edge network that exploits the higher-order statistical information among molecules. In this approach, the traditional node-network representing the first-order statistics distinguishes the disease from the normal state, whereas the edge-network representing the higher-order statistics (ENA: edge-network analysis) distinguishes the pre-disease state from the normal state. At the molecular level, a biological system can be described by a stochastic dynamics model comprising a master equation or stochastic differential equations [52] . By linearizing the system and assuming a Gaussian distribution of the components, the system can be exactly expressed by two sets of equations; one evolving the mean vector of molecules (first-order statistical representation), and the other evolving the covariance matrix of molecules (second-order statistical representation). If the equations involving the covariance matrix are omitted from this model, the model reduces to the traditional node (molecular) networks (such as gene and protein interaction networks) [50] , which cannot represent the stochastic dynamics of the original system. In other words, a node-network represents a biological system in the absence of stochastic fluctuation or noise. By contrast, since an edge-network reflects the second-order statistical information of a dynamical system, it captures the stochastic dynamics of the original biological system as well as the node network (assuming that the expression levels of each molecule are Gaussian-distributed). Theoretically, the first-order statistical information (node network) distinguishes between diseased and normal samples by identifying molecular biomarkers (e.g., node biomarkers). The higher-order statistical information (edgenetwork) additionally distinguishes between pre-diseased and normal samples by identifying edge biomarkers (such as dynamical network biomarkers) [50] . This additional information is crucial for early diagnosis or prediction of a disease.
A single-sample-based approach for Class II dynamical network and edge biomarkers is the DNB-S scoring method of Liu et al. [10] . This method was developed to identify the pre-disease states of single samples (given a group of normal control samples) by exploring the distributions of differential expressions of the pre-detected DNB and non-DNB molecules [10] . Intuitively, the expressions of DNB molecules should display a double-peak (bimodal) distribution in the pre-disease state but a single-peak distribution in the normal state. By contrast, the expressions of non-DNB molecules display a single-peak distribution in both normal and pre-disease states. Thus, if multiple control samples are available, the differential expression distributions between the pre-detected DNB molecules and non-DNB molecules can be estimated for any single sample. These differential distributions, recorded as the DNB-S score, can predict the pre-disease state of a test sample. When a biological system progresses from the normal to the pre-disease state, the DNB-S score alters as follows: (i) The K-L divergence of the test and control samples with regard to molecular DNB expression increases, because the expression distributions of the DNB molecules widely differ between the two samples; (ii) The K-L divergence regarding the expression distributions of the DNB and non-DNB molecules increases, because the differential distributions of the DNB molecules differ from those of non-DNB molecules in the pre-disease test sample; (iii) The K-L divergence of the test and control samples regarding the expression distributions of non-DNB molecules exhibits no significant change, because the expressions of non-DNB molecules are unaltered in the normal and pre-disease states. Collectively, these behaviors imply that if the DNB-S score of a test sample is much higher than a trained threshold, this sample is in the pre-disease state. Like its DNB predecessor, the DNB-S scoring method is a model-free approach for identifying an at-risk individual before the disease appears or seriously degrades the individual's health. Furthermore, the DNB-S scoring method fully utilizes high-dimensional data information to compensate for insufficient samples, and thus detects the pre-disease state from a single sample based on high-throughput data.
Conclusion
The "big data" era [5358] has provided exciting opportunities for biomarker study and "P4" medicine. To achieve predictive, preventive, personalized and participatory medicine [2] , we must identify accurate and reliable biomarkers for classifying and predicting the state of a test sample. This paper has reviewed the features and computational methods of various biomarkers from static nodes to dynamical edges biomarkers. Below, we highlight the special considerations of edge biomarker study.
(i) Many traditional approaches identify the discriminative networks or edges by network-based or edge-based methods. Test samples are then classified based on the genes or proteins (or gene set) involved in the identified networks or edges, rather than on the networks or edges (or their correlations) themselves. Such approaches are essentially node-biomarker based methods because the networks or edges are used only to identify discriminative genes or node-biomarkers. Zhang et al. [6] developed a novel method that represents edges in a correlation-like vector format. Although this approach identifies the discriminatively differentially correlated gene pairs as edge biomarkers, and thereby predicts the phenotype of individual test samples, more effective methods that exploit edges and their correlations are required for determining normal or diseased states of single samples.
(ii) In contrast to the first order statistics (i.e., average gene expressions) used in traditional networks or biomarkers, higher-order statistics (e.g., deviations and covariances of gene pairs as second order statistics, skewness as a third-order statistic, and kurtosis as a fourth-order statistic) provide rich information of the original systems. This additional information is excluded in traditional network analysis. In theory, the original stochastic dynamics can be fully recovered by including sufficiently high-order statistics. The edge network developed in [50] represents network nodes by their second-order statistics, and thereby significantly improves disease prediction. High-order statistical information is expected to become widely explored in future biomarker study.
(iii) Both the network and its dynamics are important facets of living organisms, and collectively characterize the states of biological systems in a reliable and stable manner. Thus, how to incorporate dynamical information into biomarkers is a key future direction. DNB theory, which merges nonlinear dynamics and statistics besides exploring the network information, detects early-warning signals of critical transitions to the disease state [7] . Although DNB can in principle determine the critical state and the leading molecules prior to drastic transition from the observed data alone, eliminating the large amount of noise and developing an efficient algorithm for accurately detecting the DNB molecules is required in future.
(iv) In addition to the "bad" molecules (e.g., disease genes), we are also interested in biomarker identification of "good" molecules (e.g., health and longevity genes) and human networks. Quantifying "health" and "wellness" states of humans is an important task requiring both network and dynamical information. This problem is closely related to resilience and robustness evaluation in systems, and can be measured by DNB theory [7] . The concept is illustrated in Figure 1 . Health eventually reaches a critical state due to gradual changes in internal or external factors, which can be measured by DNB if big dynamical data are available ( Figure 1A and C) . By detecting critical factors (including "good" molecules) and critical networks (i.e., DNB) and appropriately attenuating the "bad" molecules while enhancing the "good" molecules, we can expect to significantly improve human health (that is, we can significantly delay the critical state). These scenarios are illustrated in Figure 1A→B and C→D. In particular, DNB can detect the leading molecules and network by which the entire system begins to progress from one state (e.g., health state) to another (e.g., unhealthy state). Thus, the drastic deterioration of an individual's health can be prevented by appropriately treating or perturbing the leading molecules [7] . In other words, health and wellness can be encouraged by enhancing the "good" genes before the critical transition to disease, rather than applying treatment once the disease has appeared (Figure 1) . Such a strategy of treating "unoccurred" disease (equivalent to the pre-disease or critical state) is endorsed in the ancient Chinese text Yellow Emperor's Medicine, which states that the best doctor treats un-occurred disease, the better doctor treats occurring disease, and the inferior doctor treats occurred disease. By offering a means of detecting incipient disease, dynamical network biomarkers may significantly benefit preventative medicine and health welfare.
Similar to disease study, networks or edges could be exploited in the evolutionary study of plants and animals, Figure 1 (color online) Quantifying human health conditions and "good" genes and networks by dynamical network biomarkers. DNB can quantify the health or wellness state of a person by measuring its "distance" from the limit or critical state based on collective fluctuations of big data. The critical state of a healthy person is eventually reached by gradual changes in internal or external factors (A), which can be measured by DNB analysis of big dynamical data (C). In contrast to traditional passive treatment of "bad" molecules after disease occurrence, human health could be improved by detecting and enhancing crucial health factors (including "good" molecules) and networks (note that the members of DNB are closely related to these important molecules) before the critical transition to disease. That is, we can significantly delay the critical state or critical transition (B and D). In particular, DNB detects the leading molecules and network that initially drive the system from one state (e.g., health) to another (e.g., disease). Drastic deteriorations in health could be prevented by appropriately treating or perturbing the precursors of the diseased state.
since they largely characterize the variations used for phenotypic classification and prediction.
